68
Participants
Start Date
October 6, 2022
Primary Completion Date
January 27, 2025
Study Completion Date
March 27, 2025
RGLS8429
Solution for subcutaneous injection
Placebo
Solution for subcutaneous injection
Northeast Clinical Research Center, Bethlehem
University of Maryland School of Medicine, Nephrology, Baltimore
Southeastern Clinical Research Institute, LLC, Augusta
Mayo Clinic - Florida, Jacksonville
Elixia, Orlando
St. Clair Nephrology Research, Roseville
University of Iowa, Iowa City
Mayo Clinic - Rochester, Rochester
University of Chicago, Chicago
Research by Design, LLC, Chicago
University of Kansas Medical Center Jared Grantham Kidney Institute, Kansas City
Witchita Nephrology Group, PA, Wichita
University of Texas Southwestern Medical Center, Dallas
CARE Institute, Chubbuck
The Idaho Kidney Institute, Idaho Falls
CARE Institute, Boise
Centricity Research Phoenix Multispecialty, Mesa
Academic Medical Research Institute, Los Angeles
Swedish Center for Comprehensive Care, Seattle
Yale Nephrology Outpatient Clinic, New Haven
Tufts Medical Center, Boston
Regulus Therapeutics Inc.
INDUSTRY